AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NYRADA INC-CDI

0.495

-0.005-1.00%

Volume:48.24K

Turnover:24.30K

Market Cap:128.05M

PE:-18.04

High:0.525

Open:0.525

Low:0.495

Close:0.500

52wk High:1.435

52wk Low:0.290

Shares:258.68M

Float Shares:102.11M

Volume Ratio:0.40

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.027

EPS(LYR):-0.027

ROE:-99.95%

ROA:-53.59%

PB:13.42

PE(LYR):-18.04

Loading ...

Overview Company News Filings

Nyrada Secures US Patent for Heart Protection Drug Candidate

MT Newswires Live

Nyrada - Patent Provides 20-Year US Protection for Xolatryp from September 2024

THOMSON REUTERS

Nyrada Inc-Nyrada US Patent for Xolatryp Granted

THOMSON REUTERS

Nyrada - US Patent Part of Global Portfolio to be Filed in Australia, Europe, Japan

THOMSON REUTERS

Nyrada Raises A$12.0 Million Via Placement

Nyrada - Raises A$12.0 Mln Via Placement to Institutional and Professional Investors

THOMSON REUTERS

Nyrada - Placement Issue Price Set at A$0.62 Per Cdi

THOMSON REUTERS

Nyrada Requests Trading Halt

ASX Penny Stocks To Watch: 3 Picks Under A$200M Market Cap

Simply Wall St.

Nyrada's Xolatryp Drug Candidate Protects Cardiac Function in Preclinical Study; Shares Gain 5%

MT Newswires Live

Nyrada Inc-Preliminary Final Report

THOMSON REUTERS

Nyrada Builds Cash Balance in June Quarter With Receipt of R&D Tax Incentive

MT Newswires Live

Several Insiders Invested In Nyrada Flagging Positive News

Simply Wall St.

Nyrada Doses First Patient in Phase 2a Trial of Heart Attack Drug Candidate

MT Newswires Live

Nyrada Says Phase 2a Trial of Heart Attack Drug Candidate on Track for 2027 Completion

MT Newswires Live

Nyrada Completes Cardioprotection Pilot Study for Lead Drug Candidate

MT Newswires Live

Here's Why We're Not Too Worried About Nyrada's (ASX:NYR) Cash Burn Situation

Simply Wall St.

Nyrada Says 7 Million Unlisted Options Due to Expire in June; Shares Fall 3%

MT Newswires Live

Nyrada Says Rodent Study Shows Drug Candidate's Anti-Tumor Activity, Shares Up 14%

MT Newswires Live

Nyrada Inc-Xolatryp Enhances Anthracycline Anti-Tumour Efficacy

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/NYR.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NYR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NYR.AU\",,,,,undefined,":{"symbol":"NYR.AU","market":"AU","secType":"STK","nameCN":"NYRADA INC-CDI","latestPrice":0.495,"timestamp":1790816051462,"preClose":0.5,"halted":0,"volume":48241,"delay":0,"changeRate":-0.010000000000000009,"nameEN":"NYRADA INC-CDI","floatShares":102113109,"shares":258681500,"eps":-0.02744,"marketStatus":"Trading","change":-0.005,"latestTime":"10-01 11:09:31 AEST","open":0.525,"high":0.525,"low":0.495,"amount":24299,"amplitude":0.06,"askPrice":0.505,"askSize":4811,"bidPrice":0.495,"bidSize":946,"shortable":3,"etf":0,"ttmEps":-0.02744,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790834400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.5,"openAndCloseTimeList":[[1790812800000,1790834400000]],"volumeRatio":0.398294,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NYR.AU","preClose":0.465,"auctionPrice":0.5,"auctionVolume":8428,"auction":3,"marketStatus":"盘后竞价","timestamp":1790748590709}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NYR.AU\",,,,,undefined,":{"symbol":"NYR.AU","floatShares":102113109,"roa":"-53.59%","roe":"-99.95%","lyrEps":-0.02744,"volumeRatio":0.398294,"shares":258681500,"dividePrice":0,"high":0.525,"amplitude":0.06,"preClose":0.5,"low":0.495,"week52Low":0.29,"pbRate":"13.42","psRate":"63.66","week52High":1.435,"institutionHeld":0,"latestPrice":0.495,"committee":-0.671357,"eps":-0.02744,"divideRate":0,"volume":48241,"delay":0,"ttmEps":-0.02744,"open":0.525,"prevYearClose":1.12,"prevWeekClose":0.52,"prevMonthClose":0.5,"prevQuarterClose":0.5,"fiveDayClose":0.495,"twentyDayClose":0.72,"sixtyDayClose":0.41},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NYR.AU\",params:#limit:5,,,undefined,":[{"date":"2023-07-28","symbol":"NYR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690502400000,"name":null,"time":"","dateTimestamp":1690466400000,"actualEps":null},{"date":"2023-04-29","symbol":"NYR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1682726400000,"name":null,"time":"","dateTimestamp":1682690400000,"actualEps":null},{"market":"AU","date":"2022-08-29","symbol":"NYR.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1661695200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NYR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NYR.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672780308","title":"Nyrada Secures US Patent for Heart Protection Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2672780308","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672780308?lang=en_us&edition=fundamental","pubTime":"2026-10-01 05:39","pubTimestamp":1790804385,"startTime":"0","endTime":"0","summary":"Nyrada  secured a US composition-of-matter patent for Xolatryp, strengthening intellectual property protection for the drug candidate's chemical structure against unauthorized manufacture, use, sale, or import, according to an Australian bourse filing on Wednesday after market hours.Xolatryp is being developed to protect the heart tissue from damage.The patent has a 20-year term from its September 2024 filing date and is part of the company's broader global patent strategy, with applications planned in key markets, including Australia, Europe, and Japan, the filing added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096","USRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671731472","title":"Nyrada - Patent Provides 20-Year US Protection for Xolatryp from September 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2671731472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671731472?lang=en_us&edition=fundamental","pubTime":"2026-09-30 14:23","pubTimestamp":1790749383,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUE1XS8SH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NYR.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671731232","title":"Nyrada Inc-Nyrada US Patent for Xolatryp Granted","url":"https://stock-news.laohu8.com/highlight/detail?id=2671731232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671731232?lang=en_us&edition=fundamental","pubTime":"2026-09-30 14:23","pubTimestamp":1790749383,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUE1XS8SH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671273140","title":"Nyrada - US Patent Part of Global Portfolio to be Filed in Australia, Europe, Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2671273140","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671273140?lang=en_us&edition=fundamental","pubTime":"2026-09-30 14:23","pubTimestamp":1790749383,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUE1XS8SH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669136582","title":"Nyrada Raises A$12.0 Million Via Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669136582","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669136582?lang=en_us&edition=fundamental","pubTime":"2026-09-21 09:25","pubTimestamp":1789953952,"startTime":"0","endTime":"0","summary":"BRIEF-Nyrada Raises A$12.0 Million Via PlacementSept 21 (Reuters)-Nyrada IncNYR.AX:RAISES A$12.0 MILLION VIA PLACEMENT TO INSTITUTIONAL AND PROFESSIONAL INVESTORSPLACEMENT ISSUE PRICE SET AT A$0.62 PER CDIFurther company coverage:NYR.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45A0PM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669381971","title":"Nyrada - Raises A$12.0 Mln Via Placement to Institutional and Professional Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669381971","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669381971?lang=en_us&edition=fundamental","pubTime":"2026-09-21 07:31","pubTimestamp":1789947089,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260920:nFWN45A0PM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NYR.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669138190","title":"Nyrada - Placement Issue Price Set at A$0.62 Per Cdi","url":"https://stock-news.laohu8.com/highlight/detail?id=2669138190","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669138190?lang=en_us&edition=fundamental","pubTime":"2026-09-21 07:31","pubTimestamp":1789947089,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260920:nFWN45A0PM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668939763","title":"Nyrada Requests Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2668939763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668939763?lang=en_us&edition=fundamental","pubTime":"2026-09-17 07:15","pubTimestamp":1789600539,"startTime":"0","endTime":"0","summary":"BRIEF-Nyrada Requests Trading HaltSept 17 (Reuters)-Nyrada IncNYR.AX:TRADING HALT REQUESTED PENDING ANNOUNCEMENT ON MATERIAL CAPITAL RAISINGFurther company coverage:NYR.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nFWN4580FV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662508557","title":"ASX Penny Stocks To Watch: 3 Picks Under A$200M Market Cap","url":"https://stock-news.laohu8.com/highlight/detail?id=2662508557","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662508557?lang=en_us&edition=fundamental","pubTime":"2026-08-26 03:02","pubTimestamp":1787684525,"startTime":"0","endTime":"0","summary":"The ASX is poised for a strong start today, buoyed by positive corporate reporting and lower oil prices, even as global markets face mixed signals. For investors interested in exploring beyond the major players, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities. Despite their somewhat outdated name, these stocks can present valuable growth potential when backed by solid financial fundamentals.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3072000-choice2-main-header/1585186655182","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3072000-choice2-main-header/1585186655182"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-al3/aml3d-shares/news/asx-penny-stocks-to-watch-3-picks-under-a200m-market-cap","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-al3/aml3d-shares/news/asx-penny-stocks-to-watch-3-picks-under-a200m-market-cap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALC.AU","AL3.AU","NYR.AU","BK7088","BK7094","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661558592","title":"Nyrada's Xolatryp Drug Candidate Protects Cardiac Function in Preclinical Study; Shares Gain 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661558592","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661558592?lang=en_us&edition=fundamental","pubTime":"2026-08-21 08:54","pubTimestamp":1787273690,"startTime":"0","endTime":"0","summary":"Nyrada  said its Xolatryp drug candidate provided significant protection to cardiac function against progressive doxorubicin-induced cardiotoxicity in a preclinical study, according to a Friday filing with the Australian bourse.Doxorubicin is an anthracycline drug widely used as a first-line treatment for both solid and metastatic tumors, and is considered a \"backbone drug\" in oncology, the company said.Doxorubicin treatment weakened the heart's ability to pump and empty blood effectively, and Xolatryp delivered benefits across four key measures of heart performance that were negatively impacted by doxorubicin, Nyrada said.The magnitude of functional protection was comparable to dexrazoxane, which is the only approved cardioprotective agent, per the filing.Nyrada said it will assess the design and feasibility of a potential phase 1b clinical trial of Xolatryp in the oncology setting.The company's share gained 5% in recent Friday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660845604","title":"Nyrada Inc-Preliminary Final Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2660845604","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660845604?lang=en_us&edition=fundamental","pubTime":"2026-08-18 11:05","pubTimestamp":1787022349,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nTUE6NYCPC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654096125","title":"Nyrada Builds Cash Balance in June Quarter With Receipt of R&D Tax Incentive","url":"https://stock-news.laohu8.com/highlight/detail?id=2654096125","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654096125?lang=en_us&edition=fundamental","pubTime":"2026-07-27 11:23","pubTimestamp":1785122584,"startTime":"0","endTime":"0","summary":"Nyrada  ended the June quarter with a cash balance of about AU$8.4 million, up from AU$6.7 million as of March 31, according to a Monday filing with the Australian bourse.Cash operating outflows for the June quarter totaled about AU$1.7 million, offset by AU$60,000 of interest income and the receipt of a roughly AU$2.5 million research and development tax incentive from the Australian government, per the filing.The company said its phase 2a clinical trial of Xolatryp in heart attack patients remains on track for completion next year, with the final patient expected to be dosed in mid-2027.Nyrada shares fell 1% in recent Monday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652961266","title":"Several Insiders Invested In Nyrada Flagging Positive News","url":"https://stock-news.laohu8.com/highlight/detail?id=2652961266","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652961266?lang=en_us&edition=fundamental","pubTime":"2026-07-20 06:01","pubTimestamp":1784498465,"startTime":"0","endTime":"0","summary":"Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/several-insiders-invested-in-nyrada-flagging-positive-news","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/several-insiders-invested-in-nyrada-flagging-positive-news","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NYR.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649058614","title":"Nyrada Doses First Patient in Phase 2a Trial of Heart Attack Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2649058614","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649058614?lang=en_us&edition=fundamental","pubTime":"2026-07-06 09:03","pubTimestamp":1783299790,"startTime":"0","endTime":"0","summary":"Nyrada  has initiated its PROTECT-MI phase 2a clinical trial with the dosing of the first patient evaluating its transient receptor potential canonical ion channel inhibitor Xolatryp, according to a Monday filing with the Australian bourse.The trial is a randomized, double-blind, placebo-controlled study that will follow patients for 30 days to assess safety, tolerability, and efficacy outcomes while keeping treatment allocation concealed, per the filing.The company said that trial site activation is progressing, with Sir Charles Gairdner Hospital in Perth expected to begin recruitment soon, additional Australian sites moving through regulatory approval, and expansion into New Zealand underway, the filing said.The company expects the last patient to be dosed in mid-2027, with top-line results anticipated about three months after that patient completes a 30-day follow-up visit, the filing added.The company's shares fell 2% in recent Monday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643738679","title":"Nyrada Says Phase 2a Trial of Heart Attack Drug Candidate on Track for 2027 Completion","url":"https://stock-news.laohu8.com/highlight/detail?id=2643738679","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643738679?lang=en_us&edition=fundamental","pubTime":"2026-06-16 10:53","pubTimestamp":1781578431,"startTime":"0","endTime":"0","summary":"Nyrada  said its phase 2a clinical trial evaluating the safety and preliminary efficacy of Xolatryp in heart attack patients remains on track for completion in 2027, according to a Tuesday filing with the Australian bourse.The trial is designed to assess the safety and preliminary efficacy of the drug candidate in reducing heart tissue damage and improving heart function in patients who are suffering a heart attack.Nyrada said Royal Hobart Hospital has withdrawn from the trial due to local resourcing constraints, but the company has selected Royal Perth Hospital to participate, and two additional sites are nearing activation, per the filing.Nyrada is targeting the submission of an investigational new drug application to the US Food and Drug Administration in the second half of the year.The company's shares rose 2% in recent Tuesday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640973230","title":"Nyrada Completes Cardioprotection Pilot Study for Lead Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2640973230","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640973230?lang=en_us&edition=fundamental","pubTime":"2026-06-03 12:24","pubTimestamp":1780460646,"startTime":"0","endTime":"0","summary":"Nyrada  completed a preclinical cardioprotection pilot study that confirmed the feasibility and tolerability of the planned subcutaneous dosing for its Xolatryp lead drug candidate in combination with doxorubicin, according to a Wednesday filing with the Australian bourse.The pilot study aimed to evaluate whether Xolatryp can provide a cardioprotective role in anthracycline chemotherapy, to reduce cardiotoxicity without jeopardizing anti-tumor activity, per the filing.Preliminary biomarker data from the trial showed lower levels of a clinically relevant marker of cardiac injury relative to a control group, the company said.The pilot study was not designed to show statistical significance for an efficacy readout, but it will inform the design of a larger cardiomyopathy study for which results are expected in the third quarter, Nyrada said.The company's shares fell 6% in recent Wednesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","DBB","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638650682","title":"Here's Why We're Not Too Worried About Nyrada's (ASX:NYR) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2638650682","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638650682?lang=en_us&edition=fundamental","pubTime":"2026-05-28 12:59","pubTimestamp":1779944362,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/heres-why-were-not-too-worried-about-nyradas-asxnyr-cash-bur","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/heres-why-were-not-too-worried-about-nyradas-asxnyr-cash-bur","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NYR.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637051158","title":"Nyrada Says 7 Million Unlisted Options Due to Expire in June; Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637051158","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637051158?lang=en_us&edition=fundamental","pubTime":"2026-05-21 11:32","pubTimestamp":1779334377,"startTime":"0","endTime":"0","summary":"Nyrada  said a total of about 7 million unlisted options are due to expire on June 29, including 2.9 million with an exercise price of AU$0.40, 2 million at AU$0.60, and 2 million at AU$0.90, according to a Thursday Australian bourse filing.The company's shares fell 3% in recent Thursday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636894073","title":"Nyrada Says Rodent Study Shows Drug Candidate's Anti-Tumor Activity, Shares Up 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636894073","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636894073?lang=en_us&edition=fundamental","pubTime":"2026-05-20 11:17","pubTimestamp":1779247066,"startTime":"0","endTime":"0","summary":"Nyrada (ASX:NYR) said that a rodent study demonstrated that its xolatryp drug candidate exhibits anti-tumor activity both as a monotherapy and in combination with doxorubicin, a first-line chemotherap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636898833","title":"Nyrada Inc-Xolatryp Enhances Anthracycline Anti-Tumour Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2636898833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636898833?lang=en_us&edition=fundamental","pubTime":"2026-05-20 07:13","pubTimestamp":1779232439,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nTUE5F9DST:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}